Search

Sufugolix

Rilapladib

Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

Daglutril

Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

Olmutinib

Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Cimicoxib

If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

Nomifensine

The approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.

Troxacitabine

There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

Methyl 2,5-dihydroxycinnamate